Coagulation Studies in Haemolytic Uraemic Syndrome

M. L. N. WILLOUGHBY, ANNA V. MURPHY, SHEILA McMORRIS, and F. G. JEWELL

From the Royal Hospital for Sick Children, Glasgow

Received 5 May 1972.

Coagulation studies in haemolytic uraemic syndrome. Serial coagulation investigations were performed in 4 children with the haemolytic uraemic syndrome treated with heparin by continuous infusion. 2 anuric patients showed consumption of factor V and fibrinogen early in the disease, with thrombocytopenia and raised fibrin degradation products. These changes regressed during heparin therapy and renal function fully recovered in both patients. A third patient with a mild form of the disease, normal urinary output, and only borderline thrombocytopenia did not develop demonstrable depletion of factor V or fibrinogen. In a further patient a secondary 'wave' of consumption of platelets and perhaps fibrinogen was seen late in the course of the disease. These findings confirmed the occurrence of a consumptive coagulopathy in severe cases of haemolytic uraemic syndrome.

Microangiopathic haemolytic anaemia is recognized by the development of fragmented 'burr' erythrocytes in the blood film together with a falling haemoglobin level and usually a falling platelet count. These are constant findings in the haemolytic uraemic syndrome (HUS) of childhood (Brain, 1969), and there is much experimental and pathological evidence to suggest that they are due to the deposition of fibrin within arterioles and capillaries, resulting in damage to the circulating red cells and trapping of the platelets (Brain, Dacie, and Hourihane, 1962; Brain and Hourihane, 1967; Brain et al., 1968; Rubenberg et al., 1968; Bull et al., 1968).

Whether these changes are due to purely local fibrin deposition with little systemic changes in the coagulation system, or whether they represent disseminated intravascular coagulation (DIC) with consumption of the circulating clotting factors ('consumptive coagulopathy'), has remained debatable. Hammond and Lieberman (1970) in a recent review of HUS state, 'the characteristic pattern of consumption of coagulation factors, which is seen in disseminated intravascular coagulation has not yet been seen clearly in HUS, since few systematic studies have been achieved'. In an annotation on the same subject Lanzkowsky and McCrory (1967) comment, 'In order to achieve a clearer understanding of the role of DIC, there is a great need for sequential investigation of coagulation factors to be carried out in all cases.' Of the two most recent coagulation studies in this disease, one has favoured (Sanchez Avalos et al., 1970) and the other failed to confirm a consumptive coagulopathy (Katz et al., 1971).

We have performed serial coagulation investigations before and after heparin therapy in 4 children with HUS in an effort to throw more light on this problem.

Methods

Standard haematological methods were performed as described by Dacie and Lewis (1963), and the platelet counts by the method of Brecher and Cronkite (1950). Venous blood was collected into a silicone tube containing 1 part of 3·8%, sodium citrate to 9 parts of blood. This was immediately placed in an ice and water mixture in a vacuum flask for transfer to the laboratory. The plasma was separated at 1 °C in a refrigerated centrifuge at 1500 g for 20 minutes. Thereafter, it was stored in aliquots at —30 °C for subsequent batchwise assay of individual coagulation factors. Fibrinogen and plasminogen were estimated by the method of Alkjærsig, Fletcher, and Sherry (1959), factor VIII assays were performed by the method of Hardisty and MacPherson (1962), and factor V assays by the method of Stefanini (1950). For estimation of fibrin degradation products (FDPs) 3 ml venous blood was placed in glass tubes containing 300 units Trasylol and incubated for 18 hours at 37 °C after clotting. The separated serum was...
stored at -30 °C until assay by the tanned red cell technique of Merskey, Kleiner, and Johnson (1966).

**Case Histories**

**Case 1.** At the age of 9 years she was investigated for pallor at another hospital and found to have Hb 5 g/100 ml and a reticulocyte count of 52%. The blood urea at the start of this illness was 315 mg/100 ml and had fallen to 53 mg/100 ml on discharge.

One year later, she was admitted to the same hospital with increasing pallor and vomiting after an upper respiratory infection 6 days previously. On examination she was pale with scattered petechiae. BP was 130/70 mmHg. Urine contained protein and RBCs, Hb was 7.6 g/100 ml, platelets 165,000/mm³, and reticulocytes 8%. Blood urea on admission was 310 mg/100 ml. On the assumption that she had recurrent haemolytic anaemia, prednisolone was started at a dose of 45 mg per day. She was transferred to this hospital, 6 days later. Peritoneal dialysis was begun 3 days after this when blood urea had risen to 330 mg/100 ml and the steroids were stopped. Dialysis was continued for 27 hours, lowering the blood urea to 99 mg/100 ml. For the next 17 days her condition remained static with the blood urea remaining close to 100 mg/100 ml, and her BP well controlled. IV heparin was administered as shown in Fig. 1. She improved clinically but the BP rose steadily. There was little response to guanethidine and reserpine and she began having generalized grand mal convulsions with a BP of 150/110 mmHg and died without regaining consciousness about 6 weeks after the onset of her illness.

At necropsy, the appearance of each kidney was similar, with a proportion of normal glomeruli and some totally sclerosed. In between the two extremes there were numerous glomeruli showing either capillary dilatation with engorgement, or capillary thrombi with ischaemic damage to endothelial nuclei. There were early arteriolar hypertensive changes.

**Case 2.** A 4-year-old boy was admitted with abdominal pain and vomiting and anuria for 24 hours. He was drowsy and pale with scattered petechiae. BP was 130/90 mmHg. Blood urea was 352 mg/100 ml, Hb 7.8 g/100 ml, platelets 40,000/mm³, and a blood film showed numerous burr cells. The diagnosis of HUS was made and since the child remained anuric with a rising blood urea and a falling Hb, peritoneal dialysis was started about 24 hours after admission. Intravenous heparin infusion was given 25 U/kg per hr, maintaining the capillary clotting time between 4 and 6 minutes. Peritoneal dialysis was continued for 72 hours, the blood urea then being 138 mg/100 ml. Intravenous heparin was discontinued after 60 hours because of the development of a haematoma of his right thigh, consequent upon an intramuscular injection.

After dialysis, there was a gradual rise in urinary output. The platelets rose to normal and Hb remained around 10 g/100 ml. Spherocytes and fragmented RBC persisted in the blood film for more than 6 weeks after his illness.

One year later he was well, with normal Hb, blood urea, and urine.

**Case 3.** An 8-year-old girl was admitted complaining of abdominal pain, anorexia, and weakness. 6 days before this she had diarrhoea lasting 3 days and had passed no urine from then until her admission. On examination she was an ill child with pallor and icterus but no ecchymoses. Her hydration was normal and she was normotensive. She had generalized abdominal tenderness but no guarding. Hb was 10 g/100 ml, platelets 10,000/mm³, and burr cells and spherocytes were present on a blood film. Blood urea was 486 mg/100 ml. Urine passed 24 hours after admission contained RBCs, and hyaline, granular, and cellular casts.

A diagnosis of HUS was made and peritoneal dialysis started. Heparin was given in an initial dosage of 25 U/kg per hr by continuous intravenous infusion. Peritoneal dialysis was continued for 48 hours with improvement in the child’s general condition and a fall in the blood urea to 135 mg/100 ml. 3 days after dialysis she had a generalized grand mal seizure from which she recovered well with no obvious neurological deficit. After this there was an increase in urinary output and a fall in blood urea levels to within normal limits. Heparin therapy was discontinued on the 14th day of the illness and she was discharged home well 3 weeks later. She has been seen for follow-up and was well with normal renal function as judged by creatinine clearance and no hypertension 14 months after her illness.

**Case 4.** A boy, aged 1 year 7 months was admitted with a history of diarrhoea and vomiting for 10 days. Hb was 4.5 g/100 ml, platelets 134,000/mm³, and blood urea 320 mg/100 ml. The provisional diagnosis of HUS was made and he was transferred to this hospital. He was pale and ill. There were no petechiae. BP was 130/80 mmHg. Urine contained protein and RBCs.
Blood urea was 418 mg/100 ml. Peritoneal dialysis was started and heparin was given by continuous intravenous infusion at the rate of 25 U/kg per hr. Urinary output remained around 400 ml/24 hours for the 3 days after admission. Peritoneal dialysis was carried out for a period of 30 hours, lowering the blood urea to 102 mg/100 ml. Over the first 5 days there was gradual increase in urinary output, with fall in blood urea to within normal limits. Heparin was discontinued after 5 days. The child was well with normal renal function and normal blood pressure 4 months after his illness.

**Results**

Fig. 1 shows serial platelet and fibrinogen values in Case 1. Heparin therapy was instituted after a progressive fall in platelet count and was followed by a rise in platelet count and a probably significant rise in fibrinogen level.

Table I gives the coagulation results in Case 2 both at diagnosis and after heparin therapy. Fibrinogen and factor V were pathologically low at diagnosis, but rose later. Fibrin degradation products (FDPs) were initially raised but fell later. Subsequently, the platelet count rose to normal and the patient fully recovered.

Fig. 2 shows the sequential changes in coagulation factors, platelet count, and urine output in Case 3. During the initial stages factor V was low and falling; FDPs were raised. Changes in fibrinogen and plasminogen paralleled factor V. After an increase in heparin dose to 35 U/kg per hr on day 2 these changes appeared to be reversed and followed by a rebound rise of factor V, fibrinogen, and factor VIII (AHG). After the response of coagulation factors there was a rise in platelet count, a return of urine flow, and a gradual fall in FDPs. The patient fully recovered.

In Case 4 without thrombocytopenia the fibrinogen was 280 mg/100 ml, factor V 145\%, factor VIII 140\%, and plasminogen 4.9 casein units/ml. There were no significant changes in these values over the succeeding 8 days. The FDPs, however, were raised to 160 \(\mu\)g/ml at diagnosis and progressively fell to 20 \(\mu\)g/ml over the next 4 days. He had a 'high output' type of renal failure and fully recovered.

**Discussion**

**Evidence of a consumptive coagulopathy.** The findings in Case 2 provide what is probably the clearest evidence yet reported of a consumptive coagulopathy during the early stage of HUS. The pathologically low 'consumable' coagulation factors V and fibrinogen (17\% and 61 mg/100 ml) in association with raised FDPs (160 \(\mu\)g/ml) at the time of diagnosis indicate a severe degree of intravascular coagulation and fibrin deposition.
The microangiopathic haemolytic anaemia and low plasminogen during this period are similarly consistent with intravascular coagulation. The coagulation data for this patient (Table I) would widely be accepted as diagnostic of DIC (Corrigan, Ray, and May, 1968; Deykin, 1970; Hathaway, 1970). Likewise the initial and sequential findings in Case 3 provide similar evidence of intravascular coagulation (Fig. 2). The ‘rebound’ rises of factors V and VIII to around 200% after heparin are particularly characteristic of preceding DIC (Hathaway, 1970).

The particular point which Case 1 showed was the ‘wave’ of platelet, and perhaps fibrinogen, consumption occurring at some time after the initial diagnosis of HUS, and their response to heparin. She died later of hypertensive encephalopathy and the necropsy showed microthrombi in the glomerular capillaries. Heparin had been stopped some weeks before death.

Case 4 did not show a consumption of coagulation factors. Clinically he was also the mildest affected of our 4 patients, never suffering from anuria or oliguria. The platelet count was 130,000/mm³ at diagnosis, and the lowest subsequent count was 82,000 compared to nadirs of 18,000, 38,000, and 22,000 in Cases 1, 2, and 3, respectively. Raised FDPs were the only evidence of intravascular coagulation. It seems likely that in parallel with this patient’s milder renal manifestations there was also a milder degree of intravascular coagulation, without actual depletion of circulating coagulation factors. It is known, for instance, that increased catabolism of fibrinogen can occur in patients with microangiopathic haemolytic anaemia without actual lowering of the circulating fibrinogen level (Baker et al., 1968).

**Comparison with previous coagulation studies in HUS.** Table II lists previous observations of the coagulation system in children with HUS. Many of the findings are suggestive of consumptive coagulopathy but few are conclusive. Sequential studies from an early stage of the disease have been relatively lacking. The series of 16 infants reported by Katz et al. (1971) included only 5 with anuria and only 2 with platelet counts below 50,000/mm³. The isolated coagulation factors, however, were not significantly abnormal in any case.

The data from other groups suggest that increases in FDPs and decreases in platelet count are more sensitive than fibrinogen levels. The fibrinogen will be decreased in only about 30% of cases of HUS (Hathaway, 1966). The factor VIII level was below normal in 7/26 cases in our series. There was no evidence that heparin, which was administered in all cases, influenced the laboratory findings. Indeed, the FDPs fell somewhat, but this was not consistent enough to suggest that the fibrinogen and factor VIII levels were returned to normal by heparin therapy.

**TABLE I**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Fibrinogen (mg/100 ml)</th>
<th>Factor V (%)</th>
<th>Factor VIII (%)</th>
<th>FDPs (µg/ml)</th>
<th>Platelets (per mm³)</th>
<th>Plasminogen (casein units/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanchez Avalos et al. (1970)*</td>
<td>160 (1/26)</td>
<td>&lt;55 (6/26)</td>
<td>&lt;50 (3/26)</td>
<td>+ (7/26)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Katz et al. (1971)*</td>
<td>&lt;200 (1/10)</td>
<td>&lt;50 (0/10)</td>
<td>&lt;75 (0/11)</td>
<td>+ (5/5)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Gilchrist et al. (1969)*</td>
<td>460</td>
<td>148</td>
<td>300</td>
<td>+ (1/2)</td>
<td>+ (2/2)</td>
<td>—</td>
</tr>
<tr>
<td>Monnens and Schretlen (1967)</td>
<td>540</td>
<td>220</td>
<td>500</td>
<td>—</td>
<td>+ (Spontaneous)</td>
<td>—</td>
</tr>
<tr>
<td>Utley (1970)</td>
<td>128</td>
<td>100</td>
<td>300</td>
<td>+</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Moncrieff and Glasgow (1970)</td>
<td>160</td>
<td>160</td>
<td>160</td>
<td>+</td>
<td>(512 µg/ml)</td>
<td>—</td>
</tr>
<tr>
<td>Desmit and Hart (1966)</td>
<td>88 before heparin</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hitzig et al. (1968)</td>
<td>Low</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Sharpstone et al. (1968)</td>
<td>—</td>
<td>—</td>
<td>+ (1/2)</td>
<td>+ (2/2)</td>
<td>+ (3/3)</td>
<td>—</td>
</tr>
<tr>
<td>Künzler and Aalam (1964)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+ (5/5)</td>
<td>—</td>
</tr>
<tr>
<td>Fiel and Phibbs (1966)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Pathologically high levels of fibrinogen, factor V, and factor VIII were frequent in these series.

Note: Fractions (e.g. 1/26) indicate the number of patients of the series showing the abnormality in question.
investigations performed at varying times from diagnosis failed to show a consumptive coagulopathy but FDPs were raised in the 5 cases tested. Our Case 4 appears to be similar to the patients in this series.

The most extensive coagulation investigation so far reported in this disease is that by Sanchez Avalos et al. (1970). Multiple factors were assayed at 5 to 7 day intervals, starting 6 or more days after the onset of the disease. Though they found no evidence of consumptive coagulopathy at that stage of the disease, thrombocytopenia, the longer lasting abnormality after DIC, was initially present in every patient. This was often associated with abnormally high levels of fibrinogen and factor VIII consistent with a 'rebound' phenomenon after DIC. In 3 patients these authors observed 'recurrent episodes of acute intravascular consumption'. These were seen only in children with an extremely severe and sometimes fatal course. Sequential coagulation data were shown for one case where there was a 'wave' of consumption of both platelets and coagulation factors developing between 2 and 3 weeks from the onset of symptoms. These authors therefore appear to have recorded the same changes as in our Cases 2 and 3, but at a later stage of the disease rather than at presentation. It is continuing or recurrent intravascular coagulation that justifies the trial of anticoagulants in this disease. This appears to have occurred in our Case 1 as well as in the 3 patients of Sanchez Avalos et al. (1970). These coagulation studies indicate the severity and reversible nature of the intravascular coagulation but are unable to define whether this is truly disseminated (i.e. DIC) or localized to the kidney.

We gratefully acknowledge the co-operation of Professors J. H. Hutchinson and G. C. Arneil, and Drs. R. A. Shanks and D. H. Wallace under whose clinical care these patients were being treated, and of the numerous nursing staff involved with the patients' care.

REFERENCES


Coagulation Studies in Haemolytic Uraemic Syndrome


Addendum

Since submitting this paper a fifth patient with HUS has been investigated. The initial platelet count was 95,000/mm³, fibrinogen 172 mg/100 ml, and FDPs 80 μg/ml. Factor V was 130%. During heparinization the platelets and fibrinogen rose to normal, the FDPs fell to normal and the factor V rose to 220%. Urine flow returned after 5 days on heparin. The severity of the coagulation defect appeared to be similar to that in Case 1 described above, but the patient has survived.

Correspondence to Dr. M. L. N. Willoughby, Royal Hospital for Sick Children, Yorkhill, Glasgow C3.